TRACON Pharmaceuticals, Inc.

TCON

US89237H3084

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 01:25:57 18/07/2024 am IST			5-day change	1st Jan Change
0.6302 ^USD	+1.28%		-12.47%	-82.00%

02/07	TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from S&P TMI Index	CI
01/07	TRACON Pharmaceuticals to Explore Strategic Alternatives Leveraging its In-House Product Development Platform	CI

TRACON Pharmaceuticals, Inc. has completed an IPO in the amount of $36.00 million.

January 29, 2015 at 10:30 am IST

TRACON Pharmaceuticals, Inc. has completed an IPO in the amount of $36.00 million.

Offer Details:
Security Type: Common Stock
Offered: 3600000
Price/Range: 10.00

Latest news about TRACON Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from S&P TMI Index	02/07	CI
TRACON Pharmaceuticals to Explore Strategic Alternatives Leveraging its In-House Product Development Platform	02/07	CI
Sector Update: Health Care Stocks Slipping in Afternoon Trading	01/07	MT
Sector Update: Health Care	01/07	MT
Tracon to Explore Strategic Alternatives After Trial Misses Target	01/07	MT
TRACON Pharmaceuticals Announces Termination of Envasarc Trial and Will Explore Strategic Alternatives Leveraging Its In-House Product Development Platform	01/07	CI
TRACON Pharmaceuticals, Inc.(OTCPK:TCON) dropped from NASDAQ Composite Index	27/06	CI
TRACON Pharmaceuticals, Inc. Announces Resignation of David Lazar as Chief Business Development Officer	22/06	CI
Top Premarket Decliners	21/06	MT
TRACON Pharmaceuticals, Inc. Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for Trc102, A Dna Damage Repair Inhibitor, in Recurrent Glioblastoma Patients	11/06	CI
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Transcript : TRACON Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024	15/05
Earnings Flash (TCON) TRACON PHARMACEUTICALS Posts Q1 Revenue $100,000	15/05	MT
Tracon Pharmaceuticals, Inc. Appoints David Lazar as Chief Business Development Officer	13/05	CI
TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned	03/04	CI
HC Wainwright Adjusts Price Target on TRACON Pharmaceuticals to $6 From $7, Keeps Buy Rating	06/03	MT
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
Transcript : TRACON Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 05, 2024	06/03
Earnings Flash (TCON) TRACON PHARMACEUTICALS Reports Q4 Revenue $3M, vs. Street Est of $1.5M	06/03	MT
TRACON Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03	CI
TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial	20/12	CI
Tracon Licenses Product Development Platform for $3 Million Upfront Payment; Shares Jump	20/11	MT
TRACON Pharmaceuticals, Inc. Announces License of Product Development Platform for $3.0 Million Upfront Payment	20/11	CI
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks	10/11	MT
Exchange-Traded Funds, Equity Futures Rise After Fed Chief's Comments	10/11	MT

Chart TRACON Pharmaceuticals, Inc.

Duration

Period

More charts

TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Companyâs clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.

Sector

Pharmaceuticals

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.6302

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
TRACON PHARMACEUTICALS, INC.	-82.00%	1.69M
CSL LIMITED	+8.54%	100B
SAMSUNG BIOLOGICS CO.,LTD.	+11.97%	43.89B
BIOGEN INC.	-11.76%	33.24B
UCB	+79.66%	29.36B
BIOMARIN PHARMACEUTICAL INC.	-12.20%	16.08B
INCYTE CORPORATION	+4.00%	14.68B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-1.90%	12.87B
ALTEOGEN INC.	+178.17%	10.55B
SWEDISH ORPHAN BIOVITRUM AB	+4.72%	8.83B

Biopharmaceuticals